Commercial Novartis shares fall as Entresto sales weaken PharmaphorumNovartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026.CardiovascularRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Novartis is showing the effects of its patent cliff more strongly, with generic competition hitting sales and profits in the first quarter of 2026. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Seaport and Hemab target $180m IPOs as biotech listings accumulateNext: Merck KGaA and Remepy join forces to develop combo drug-digital therapies Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
